Cormorant Asset Management, LP

Investment Portfolio & 13F Holdings Analysis

About
CIK: 0001583977
Type: FundHoldings: 42Value: $1.2BLatest: 2025Q1

Cormorant Asset Management, LP is an institutional investment manager that filed its latest Form 13F for 2025Q1, reporting 42 holdings worth $1.2 billion. Form 13F filings provide transparency into the equity holdings of institutional investment managers with over $100 million in assets under management. This page displays the most recent portfolio holdings, allowing investors to track position changes, new investments, and portfolio composition.

Filing Details

13F-HR2025-03-31
Report Date
2025-03-31
Filing Date
2025-05-15
Total Holdings
42
Total Value
1218119015
Accession Number
0001583977-25-000005
Form Type
13F-HR
Manager Name
Cormorant-Asset-Management-Lp
Data Enrichment
88% identified
37 identified5 unidentified

Holdings

42 positions • $1.2B total value
Manager:
Search and click to pin securities to the top
Page 1 of 3
MoonLake Immunotherapeutics
Shares:8.5M
Value:$331.9M
% of Portfolio:27.2% ($331.9M/$1.2B)
Edgewise Therapeutics, Inc.
Shares:4.1M
Value:$90.2M
% of Portfolio:7.4% ($90.2M/$1.2B)
BridgeBio Pharma, Inc.
Shares:2.0M
Value:$69.1M
% of Portfolio:5.7% ($69.1M/$1.2B)
Arcellx, Inc.
Shares:1.1M
Value:$68.9M
% of Portfolio:5.7% ($68.9M/$1.2B)
Praxis Precision Medicines, Inc.
Shares:1.7M
Value:$66.1M
% of Portfolio:5.4% ($66.1M/$1.2B)
EyePoint Pharmaceuticals, Inc.
Shares:8.3M
Value:$45.1M
% of Portfolio:3.7% ($45.1M/$1.2B)
INSMED Inc
Shares:525.0K
Value:$40.1M
% of Portfolio:3.3% ($40.1M/$1.2B)
10919W405
Shares:1.1M
Value:$38.2M
% of Portfolio:3.1% ($38.2M/$1.2B)
G4444H101
Shares:2.9M
Value:$32.9M
% of Portfolio:2.7% ($32.9M/$1.2B)
Centessa Pharmaceuticals plc
Shares:2.3M
Value:$32.5M
% of Portfolio:2.7% ($32.5M/$1.2B)
Merus N.V.
Shares:740.0K
Value:$31.1M
% of Portfolio:2.6% ($31.1M/$1.2B)
Rapport Therapeutics, Inc.
Shares:2.9M
Value:$29.5M
% of Portfolio:2.4% ($29.5M/$1.2B)
Axsome Therapeutics, Inc.
Shares:250.0K
Value:$29.2M
% of Portfolio:2.4% ($29.2M/$1.2B)
Pharvaris N.V.
Shares:1.5M
Value:$23.0M
% of Portfolio:1.9% ($23.0M/$1.2B)
GH Research PLC
Shares:2.0M
Value:$22.2M
% of Portfolio:1.8% ($22.2M/$1.2B)
Arcutis Biotherapeutics, Inc.
Shares:1.4M
Value:$21.1M
% of Portfolio:1.7% ($21.1M/$1.2B)
Tarsus Pharmaceuticals, Inc.
Shares:400.0K
Value:$20.5M
% of Portfolio:1.7% ($20.5M/$1.2B)
ARS Pharmaceuticals, Inc.
Shares:1.6M
Value:$20.1M
% of Portfolio:1.7% ($20.1M/$1.2B)
Crinetics Pharmaceuticals, Inc.
Shares:600.0K
Value:$20.1M
% of Portfolio:1.7% ($20.1M/$1.2B)
CG Oncology, Inc.
Shares:775.0K
Value:$19.0M
% of Portfolio:1.6% ($19.0M/$1.2B)